Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Bohlen

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
Bone Marrow Transplantation|August 10, 2000
Treatment of patients with malignant lymphomas with monoclonal antibodiesH Tesch, A Engert, O Manzke, et al.
Medizinische Klinik (Munich, Germany : 1983)|March 15, 1994
[Chronic fatigue syndrome]S Schmitz, H Tesch, H Bohlen, et al.
Journal of Stem Cells & Regenerative Medicine|April 3, 2014
Generation and selection of hepatocyte-like cells from transgenic murine embryonic stem cells at different differentiation stagesE Gabriel, E Kolossov, H Bohlen, et al.
The European Physical Journal. E, Soft Matter|February 28, 2008
Intrusion of fluids into nanogrooves: how geometry determines the shape of the gas-liquid interfaceH Bohlen, A O Parry, E Díaz-Herrera, et al.
Annals of Hematology|May 10, 2000
Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's diseaseH Bohlen, M Kessler, M Sextro, et al.
Cancer Immunology, Immunotherapy : CII|January 22, 1998
CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphomaO Manzke, S Titzer, H Tesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Immunotoxins: is there a clinical value?C Gottstein, U Winkler, H Bohlen, et al.
Nature Biotechnology|July 1, 1997
Retargeting serum immunoglobulin with bispecific diabodiesP Holliger, M Wing, J D Pound, et al.
International Immunology|November 4, 2000
Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentationC Carstens, D K Newman, H Bohlen, et al.
Zeitschrift Fur Rheumatologie|June 17, 1998
Inhibition of interleukin-8 synthesis by intraarticular methotrexate therapy in patients with rheumatoid arthritisI K Gao, C Leins, H Bohlen, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
Bone Marrow Transplantation|August 10, 2000
Treatment of patients with malignant lymphomas with monoclonal antibodiesH Tesch, A Engert, O Manzke, et al.
Medizinische Klinik (Munich, Germany : 1983)|March 15, 1994
[Chronic fatigue syndrome]S Schmitz, H Tesch, H Bohlen, et al.
Journal of Stem Cells & Regenerative Medicine|April 3, 2014
Generation and selection of hepatocyte-like cells from transgenic murine embryonic stem cells at different differentiation stagesE Gabriel, E Kolossov, H Bohlen, et al.
The European Physical Journal. E, Soft Matter|February 28, 2008
Intrusion of fluids into nanogrooves: how geometry determines the shape of the gas-liquid interfaceH Bohlen, A O Parry, E Díaz-Herrera, et al.
Annals of Hematology|May 10, 2000
Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's diseaseH Bohlen, M Kessler, M Sextro, et al.
Cancer Immunology, Immunotherapy : CII|January 22, 1998
CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphomaO Manzke, S Titzer, H Tesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Immunotoxins: is there a clinical value?C Gottstein, U Winkler, H Bohlen, et al.
Nature Biotechnology|July 1, 1997
Retargeting serum immunoglobulin with bispecific diabodiesP Holliger, M Wing, J D Pound, et al.
International Immunology|November 4, 2000
Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentationC Carstens, D K Newman, H Bohlen, et al.
Zeitschrift Fur Rheumatologie|June 17, 1998
Inhibition of interleukin-8 synthesis by intraarticular methotrexate therapy in patients with rheumatoid arthritisI K Gao, C Leins, H Bohlen, et al.
Pageof 7